

# MEDICAL BioHealth EUR

## Brief information

WKN: 941135 - ISIN: LU0119891520

## Fund management

## Contact person



**Mario Linimeier:**  
Managing Partner, Head of  
Portfolio Management



**Dr. Alexander Jenke:**  
Deputy Head of Portfolio  
Management, Authorised  
Signatory



**Martina Beran:**  
Head of Sales  
+49(0) 821-259351-15  
mberan@medicalstrategy.de



**„Research leads to impact.  
Impact leads to growth.“**

From innovation  
outperformance

4 tailwind factors for  
biotech

1. **Innovative biotech stocks**
2. **Focus on small and mid-cap companies**
3. **Focus on leading developers of innovative therapies**
4. **Scientists as portfolio managers**
5. **Successful investment track record & outperformance compared to other strategies**


**Expiring patents** are increasing the pressure on Big Pharma – M&A activity is on the rise

**Strong fundamentals:** Product development is largely unaffected by macroeconomic factors; demand for essential medicines is considered to be relatively recession-proof

**Healthcare as a macro trend:** Demographic change and technological progress point to the sector's growing importance in the long term


**Low valuation levels:** Some small and mid-caps are currently valued below cash

## Performance since inception



Note: The BVI method shows the fund's performance on a reinvested basis, but does not take into account individual costs such as initial charges.

## Rolling annual performance



Right-hand chart: Past performance is not a reliable indicator of future results. Gross performance (BVI method) takes into account all costs incurred at fund level (e.g. management fees) whilst net performance also includes the initial sales charge. Further costs may be incurred individually at client level (e.g. custody fees commissions and other charges). Source: Anevis Solutions GmbH own representation. Left-hand chart: As at 30 April 2026; Source: vwd; Price indices in EUR; The previous day's closing prices were used for the calculation of index performance and exchange rate conversion. As the fund is primarily invested in North America the time difference has been taken into account. Fund: Performance calculated using gross value growth (BVI method). The initial charge (on investment and reinvestment) was not taken into account nor were individual costs such as custody fees. If the initial charge and custody fees were included the performance would be lower. Past performance is not an indicator of future performance and is no guarantee of future success.

## 5 therapeutic areas with potential for structural growth

Cancer	Rare diseases	Autoimmune diseases	Cardiometabolic diseases	CNS Disorders
--------	---------------	---------------------	--------------------------	---------------

## Awards



## All fund facts



**Legal notice:** Past performance is not a reliable indicator of future results. This is a non-binding marketing communication. It is provided for information purposes only and does not constitute a public offer, a recommendation, advice or a solicitation to buy or sell fund units, nor should it be regarded as an invitation to make an offer to enter into a contract for investment services or ancillary services. It does not constitute a recommendation to buy or sell. The information and assessments contained herein do not constitute investment advice or any other recommendation. They are no substitute for individual investment advice. No assurance can be given that the investment objectives will be achieved. Past performance is no guarantee and no indicator of future performance. Please read the prospectus and the Key Information Document (KID) before making a final investment decision. The binding basis for the purchase of the fund is the Key Information Document (KID), the currently valid prospectus together with the management regulations or articles of association, the most recently published and audited annual report and the most recently published unaudited half-yearly report, which are available free of charge in German from the management company Hauck & Aufhäuser Fund Services S.A., 1c, rue Gabriel Lippmann, 5365 Munsbach, Luxembourg and at <https://medicalstrategy.de/fonds/medical-bio-health>. You can also obtain further information by calling +49-821-259351-14 or by emailing [relations@medicalstrategy.de](mailto:relations@medicalstrategy.de). Further detailed information on the opportunities and risks is contained in the prospectus and the key investor information document. Risk class 5 is based on the assumption that the recommended holding period is adhered to. The risk indicator can have a value between 1 and 7. The actively managed fund portfolio is not managed in relation to a benchmark index. Tax treatment depends on the personal circumstances of the respective investors and may be subject to future changes. The funds of Medical Strategy GmbH were established under German law and are authorised for distribution in Germany, Austria, the Netherlands and Spain. The units of this fund are not intended for distribution in the USA or to US citizens. The management company may decide to revoke the arrangements it has made for the distribution of the units of its undertakings for collective investment in accordance with Article 93a of Directive 2009/65/EC. Information on investor rights is available at <https://www.hal-privatbank.com/>. The opinions expressed in this product information reflect the current, carefully prepared assessment of Medical Strategy GmbH; these may change at any time without prior notice. Medical Strategy GmbH and third parties from whom Medical Strategy GmbH obtains information accept no liability for the correctness, completeness, timeliness, accuracy or availability of the data made available and displayed as part of this information service, despite careful procurement and provision. Medical Strategy GmbH and anevis solutions GmbH, which technically produces the presentation/monthly reports, have not verified the data themselves and accept no liability for losses caused by the use of this information or arising in connection with the use of this information. Use of this information is at your own risk. Any unauthorised use of this document, in particular its reproduction, processing, forwarding or publication, is prohibited. The author of this document, as well as its affiliated companies, expressly exclude any liability for the accuracy, completeness or timeliness of the information contained herein and the opinions expressed. Any past performance figures, back-test data or historical or forward-looking simulations contained in this document are no guarantee of future developments. An investment refers to the purchase of fund units and not directly to the underlying assets. As at 26 May 2026. In the "Biotechnology Equity Funds" category, MEDICAL BioHealth secured third place over 10 years and first place over 20 years. On methodology: Since 2006, Curio and its sister publications Börse Online and Curio am Sonntag have been presenting the coveted Curio FundAwards. With these, we recognise the funds and ETFs that have achieved the best, second-best and third-best performance in their respective investment categories over 1, 3, 5, 10 and 20 years. Around 22,800 funds and ETFs are in the running for the 2026 FundAwards. The awards are presented across 97 asset classes and for the periods of 1 year (5,601 funds and ETFs), 3 years (5,464), 5 years (5,287), 10 years (4,508) and 20 years (1,953). The cut-off date for the assessment was 31 December 2026. Candidates for a FundAward are funds and ETFs with a volume of at least €20 million that can be easily purchased by retail investors through banks or on the stock exchange.

**Risks:** Credit risk: Issuers of debt securities may become insolvent; Liquidity risk: In the case of non-exchange-traded securities; Counterparty risk: The fund's counterparties may become insolvent. Risks associated with the use of derivatives: Higher potential returns are accompanied by higher risks of loss; Currency risk: Returns may rise or fall due to currency fluctuations; In general, every investment carries the risk of capital loss.